Your session is about to expire
← Back to Search
NAC Attack Trial Summary
This trial will test if N-acetylcysteine can help treat retinitis pigmentosa, an inherited retinal degeneration caused by mutations.
- Retinitis Pigmentosa
NAC Attack Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
NAC Attack Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
NAC Attack Trial Design
Find a Location
Who is running the clinical trial?
- You have had laser treatment for a certain eye condition in the past.You have an eye condition that could make it difficult to understand the study results.You have had a previous condition called uveitis in one or both of your eyes.This is a general criterion which means it applies to all potential participants. There are no specific restrictions or requirements for this criterion.You cannot take any supplements except for vitamin A.You have other health conditions or test results that suggest taking oral NAC might not be safe or it could affect your follow-up care.You have had a stroke or heart attack within the past 6 months.You have had an allergic reaction to NAC in the past.You have taken NAC (a medication) in any form within the last 4 months.You have glaucoma or another eye condition that affects your ability to see clearly.You have any eye disease other than retinitis pigmentosa that affects your ability to see clearly or have a limited field of vision.You have had eye surgery within the past 3 months.You are able to comply with the study protocol and to participate in all study visits and assessments in the investigator's judgement.You have liver disease, cystic fibrosis, asthma, or a lung condition called COPD. You also have a history of low platelet count or other blood problems that are not reversible.You have severe kidney problems and need dialysis or a kidney transplant.Criteria related to eyes that determine whether you can participate in the study.
- Group 1: Group 2 - Placebo
- Group 2: Group 1 - N-acetylcysteine
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could this treatment work for individuals over the age of 25?
"The age range for patients that this trial is looking to recruit are those that are between 18 to 65 years old."
In how many different medical practices is this research project being conducted currently?
"There are 25 clinical sites running this trial, some notable locations include McGill University in Montreal, Wilmer Eye Institute in Baltimore, and University of California - Davis."
Has N-acetylcysteine been cleared by the FDA?
"N-acetylcysteine has undergone multiple rounds of clinical testing, so it is estimated to be a safe medication with a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Stanford University, Byers Eye Institute: < 48 hours
- University of Washington, Department of Ophthalmology: < 48 hours
- Retina Foundation of the Southwest: < 48 hours
Share this study with friends